{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:12:27Z","timestamp":1789035147774,"version":"build-2803163510"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1097\/01.mph.0000212991.64435.f0","type":"journal-article","created":{"date-parts":[[2006,9,26]],"date-time":"2006-09-26T04:21:30Z","timestamp":1159244490000},"page":"585-593","source":"Crossref","is-referenced-by-count":118,"title":["Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome"],"prefix":"10.1097","volume":"28","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Travelstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Civitello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Greffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin D.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Kalinyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy H.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210227","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00002826-199206000-00002","article-title":"The neurobiology of opsoclonus-myoclonus syndrome","volume":"15","author":"Pranzatelli","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"R2-8-20210227","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","article-title":"CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity","volume":"19","author":"Pranzatelli","year":"2004","journal-title":"Mov Disord"},{"key":"R3-8-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-5728(95)00126-3","article-title":"Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid","volume":"63","author":"Svenningsson","year":"1995","journal-title":"J Neuroimmunol"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/brain\/awg118","article-title":"B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas","volume":"126","author":"Anthony","year":"2003","journal-title":"Brain"},{"issue":"suppl","key":"R5-8-20210227","first-page":"1","article-title":"Autoreactive T and B cells in nervous system diseases","volume":"142","author":"Sun","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00319706","article-title":"The proliferation rate of T and B lymphocytes in cerebrospinal fluid","volume":"238","author":"Thomas","year":"1991","journal-title":"J Neurol"},{"key":"R7-8-20210227","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2249.1995.tb03133.x","article-title":"B-cells capable of spontaneous IgG secretion in cerebrospinal fluid from patients with multiple sclerosis: dependency of local IL-6 production","volume":"101","author":"Perez","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"R8-8-20210227","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0022-3476(97)70272-5","article-title":"Serum antibodies in childhood opsoclonus-myoclonus syndrome","volume":"130","author":"Connolly","year":"1997","journal-title":"J Pediatr"},{"key":"R9-8-20210227","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00043426-200007000-00007","article-title":"Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus","volume":"22","author":"Antunes","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-8-20210227","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.10462","article-title":"Autoantigen diversity in the opsoclonus-myoclonus syndrome","volume":"53","author":"Bataller","year":"2003","journal-title":"Ann Neurol"},{"key":"R11-8-20210227","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.20539","article-title":"Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome","volume":"58","author":"Blaes","year":"2005","journal-title":"Ann Neurol"},{"key":"R12-8-20210227","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1016\/S0021-9258(18)60461-2","article-title":"Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C","volume":"264","author":"Valentine","year":"1989","journal-title":"J Biol Chem"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R14-8-20210227","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"R15-8-20210227","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"14","key":"R16-8-20210227","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"R17-8-20210227","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1034\/j.1600-0609.2001.066006408.x","article-title":"Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia","volume":"66","author":"Faurschou","year":"2001","journal-title":"Eur J Haematol"},{"key":"R18-8-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic phemigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"key":"R19-8-20210227","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune hemolytic anemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"R20-8-20210227","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Int Med"},{"key":"R21-8-20210227","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthr Rheumat"},{"key":"R22-8-20210227","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"R23-8-20210227","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-2141.2001.0115_1cr-4.x","article-title":"Rituximab in a case of cold agglutinin disease","volume":"115","author":"Zaja","year":"2001","journal-title":"Br J Haematol"},{"key":"R24-8-20210227","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"key":"R25-8-20210227","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"R26-8-20210227","first-page":"S197","article-title":"Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis","volume":"46","author":"Edwards","year":"2002","journal-title":"Arthritis Rheumat"},{"key":"R27-8-20210227","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"key":"R28-8-20210227","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"R29-8-20210227","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"key":"R30-8-20210227","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R31-8-20210227","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"key":"R32-8-20210227","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11926-003-0020-x","article-title":"B cell depletion therapy in systemic lupus erythematosus","volume":"5","author":"Anolik","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"R33-8-20210227","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000067271","article-title":"Rituximab for immune hemolytic anemia following T- and B-cell depleted hematopoietic stem cell transplantation","volume":"109","author":"Corti","year":"2003","journal-title":"Acta Haematol"},{"key":"R34-8-20210227","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"R35-8-20210227","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with a MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"R36-8-20210227","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann Intern Med"},{"key":"R37-8-20210227","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"R38-8-20210227","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2000.18.16.3012","article-title":"Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institution","volume":"18","author":"Nishihara","year":"2002","journal-title":"J Clin Oncol"},{"key":"R39-8-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199619010-00001","article-title":"The immunopharmacology of the opsoclonus-myoclonus syndrome","volume":"19","author":"Pranzatelli","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"R40-8-20210227","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"R41-8-20210227","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R42-8-20210227","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpeds.2005.05.016","article-title":"Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone","volume":"147","author":"Pranzatelli","year":"2005","journal-title":"J Pediatr"},{"key":"R43-8-20210227","first-page":"A609","article-title":"An innovative approach to problem of sedating children with opsoclonus-myoclonus syndrome: effects on myoclonus and CSF monoamine metabolites","volume":"36","author":"Tate","year":"1994","journal-title":"Ann Neurol"},{"key":"R44-8-20210227","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mds.870130323","article-title":"Effect of high dose corticotropin on cerebrospinal fluid monoaminergic neurotransmitters or metabolites in corticotropin-responsive pediatric opsoclonus-myoclonus","volume":"13","author":"Pranzatelli","year":"1998","journal-title":"Mov Disord"},{"key":"R45-8-20210227","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3476(97)70200-2","article-title":"Immunophenotyping of blood lymphocytes in childhood. REFERENCE values for lymphocyte subpopulations","volume":"130","author":"Comans-Bitter","year":"1997","journal-title":"J Pediatr"},{"issue":"1","key":"R46-8-20210227","first-page":"A395","article-title":"CSF B-cell over-expansion in paraneoplastic opsoclonus-myoclonus: effect of rituximab, an anti-B-cell monoclonal antibody","volume":"60","author":"Pranzatelli","year":"2003","journal-title":"Neurology"},{"key":"R47-8-20210227","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1542\/peds.2004-0845","article-title":"Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus","volume":"115","author":"Pranzatelli","year":"2005","journal-title":"Pediatrics"},{"key":"R48-8-20210227","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis","volume":"46","author":"DeVita","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R49-8-20210227","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"R50-8-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/smim.1999.0168","article-title":"Leukocyte traffic in the central nervous system: the participants and their roles","volume":"11","author":"Hickey","year":"1999","journal-title":"Semin Immunol"},{"key":"R51-8-20210227","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2249.1991.tb05794.x","article-title":"Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease","volume":"86","author":"Kaveri","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"R52-8-20210227","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"R53-8-20210227","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0093-7754(03)00261-6","article-title":"Mechanism of action and resistance to monoclonal antibody therapy","volume":"30","author":"Villamor","year":"2003","journal-title":"Semin Oncol"},{"key":"R54-8-20210227","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11882-003-0072-z","article-title":"Secondary immune deficiencies associated with biological therapeutics","volume":"3","author":"Lee","year":"2003","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mph.0000212991.64435.f0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:04:51Z","timestamp":1785859491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-200609000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mph.0000212991.64435.f0","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}